CervoMed Completes Enrollment In Phase 2b RewinD-LB Clinical Trial Of Neflamapimod For The Treatment Of Patients With Dementia With Lewy Bodies

6/11/24 8:27:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CRVO alert in real time by email

- Topline data expected in December 2024 -

- Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result -

BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB).

Get the next $CRVO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRVO

Date	Price Target	Rating	Analyst
9/18/2024	$55.00	Buy	Chardan Capital Markets
7/26/2024	$35.00	Overweight	Morgan Stanley
2/15/2024	$50.00	Buy	Canaccord Genuity

More analyst ratings

$CRVO
Press Releases

Fastest customizable press release news feed in the world

CervoMed Announces Key Senior Leadership Appointments
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, Medical Science in October 2024. Dr. Ordonez was previously Chief Medical Officer at two biotech companies and has significant expertise with both early and late-stage drug development. She previously led clinical development programs in cystic fibrosis and multiple sclerosis at Vertex and Biogen, respectively. Additionally, Mark De Rosch, Ph.D., FRAPS, recently jo
11/13/24 8:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the advances made by the company towards developing the first treatment for Dementia with Lewy bodies (DLB) BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, announced today it was awarded by the Galien Foundation the Prix Galien USA 2024 prize in the Best Startup category. Cervomed was selected as one of two recipients from a total of 43 nominees in the Best Start
11/8/24 9:55:32 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's Management will participate in the following investor conferences during the month of November: Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentation Date: Thursday, November 14, 2024Time: 2:30 PM ETWebcast Link: click here Stifel 2024 Healthcare ConferenceFormat: Corporate presentation Date: Tuesday, November 19, 2024Time: 3:00 PM ETWebcast Link: click here The webcast of the presentations will be accessible in the Investor section of the CervoMed website https://www.cervomed
11/7/24 8:30:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care

$CRVO
Leadership Updates

Live Leadership Updates

CervoMed to Appoint William Elder as Chief Financial Officer
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him
5/20/24 8:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba
4/1/24 8:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp
2/7/24 8:30:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care

CervoMed Completes Enrollment In Phase 2b RewinD-LB Clinical Trial Of Neflamapimod For The Treatment Of Patients With Dementia With Lewy Bodies

Chat with this insight

Recent Analyst Ratings for
$CRVO

$CRVO
SEC Filings

CervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by CervoMed Inc.

CervoMed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$CRVO
Press Releases

Fastest customizable press release news feed in the world

CervoMed Announces Key Senior Leadership Appointments

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed to Participate in Upcoming Investor Conferences

$CRVO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

$CRVO
Leadership Updates

Live Leadership Updates

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

$CRVO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CRVO
Market Insights

Live Market Insights

$CRVO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

SEC Form 4 filed by CEO & President Alam John J

SEC Form 4 filed by Director Boger Joshua S

Canaccord Genuity Maintains Buy on CervoMed, Maintains $65 Price Target

Brookline Capital Initiates Coverage On CervoMed with Buy Rating, Announces Price Target of $63

CervoMed Announces Addition To Russell 2000 And Russell 3000 Indexes

Chardan Capital Markets initiated coverage on CervoMed with a new price target

Morgan Stanley initiated coverage on CervoMed with a new price target

Canaccord Genuity initiated coverage on CervoMed with a new price target

$CRVO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

CervoMed Completes Enrollment In Phase 2b RewinD-LB Clinical Trial Of Neflamapimod For The Treatment Of Patients With Dementia With Lewy Bodies

Chat with this insight

Recent Analyst Ratings for $CRVO

$CRVO SEC Filings

CervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by CervoMed Inc.

CervoMed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$CRVO Press Releases

Fastest customizable press release news feed in the world

CervoMed Announces Key Senior Leadership Appointments

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed to Participate in Upcoming Investor Conferences

$CRVO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

$CRVO Leadership Updates

Live Leadership Updates

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

$CRVO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CRVO Market Insights

Live Market Insights

$CRVO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

SEC Form 4 filed by CEO & President Alam John J

SEC Form 4 filed by Director Boger Joshua S

Canaccord Genuity Maintains Buy on CervoMed, Maintains $65 Price Target

Brookline Capital Initiates Coverage On CervoMed with Buy Rating, Announces Price Target of $63

CervoMed Announces Addition To Russell 2000 And Russell 3000 Indexes

Chardan Capital Markets initiated coverage on CervoMed with a new price target

Morgan Stanley initiated coverage on CervoMed with a new price target

Canaccord Genuity initiated coverage on CervoMed with a new price target

$CRVO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

Recent Analyst Ratings for
$CRVO

$CRVO
SEC Filings

$CRVO
Press Releases

$CRVO
Insider Purchases

$CRVO
Leadership Updates

$CRVO
Insider Trading

$CRVO
Market Insights

$CRVO
Analyst Ratings

$CRVO
Large Ownership Changes